COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.05M | 9.44M | 9.03M | 9.59M | 9.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.05M | 9.44M | 9.03M | 9.59M | 9.03M |
| Cost of Revenue | 5.04M | 5.02M | 4.76M | 4.86M | 7.62M |
| Gross Profit | 4.01M | 4.42M | 4.27M | 4.73M | 1.41M |
| SG&A Expenses | 10.41M | 11.30M | 11.71M | 10.44M | 7.09M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.72M | 23.86M | 24.85M | 23.60M | 12.45M |
| Operating Income | -11.66M | -14.41M | -15.82M | -14.01M | -3.42M |
| Income Before Tax | -13.82M | -17.87M | -17.07M | -15.23M | -3.03M |
| Income Tax Expenses | 1.08M | 971.00K | 496.00K | 84.00K | -1.88M |
| Earnings from Continuing Operations | -14.91 | -18.84 | -17.56 | -15.31 | -1.15 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.91M | -18.84M | -17.56M | -15.31M | -1.15M |
| EBIT | -11.66M | -14.41M | -15.82M | -14.01M | -3.42M |
| EBITDA | -10.72M | -13.27M | -14.59M | -12.75M | -1.18M |
| EPS Basic | -4.73 | -6.01 | -5.80 | -5.39 | -1.27 |
| Normalized Basic EPS | -2.14 | -2.71 | -2.71 | -2.60 | -0.94 |
| EPS Diluted | -4.73 | -6.01 | -5.80 | -5.39 | -1.27 |
| Normalized Diluted EPS | -2.14 | -2.71 | -2.71 | -2.60 | -0.94 |
| Average Basic Shares Outstanding | 12.64M | 12.57M | 11.61M | 10.32M | 10.92M |
| Average Diluted Shares Outstanding | 12.64M | 12.57M | 11.61M | 10.32M | 10.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |